Scripps Research Logo

News Release

Renowned Biochemist Joins Scripps Florida Faculty

For photo of Dr. Strosberg, go to http://www.scripps.edu/news/press/images/strosberg_donny/021005strosberg.jpg

La Jolla, CA, February 10, 2005—The Scripps Research Institute announced today the appointment of internationally renowned biochemist Arthur “Donny” Strosberg, Dr. Sci., as professor of infectology at the institute’s new facilities in Palm Beach County, Florida.

Dr. Strosberg, 59, has led teams that have made significant discoveries in the fields of biochemistry and immunology at the University of Paris, the Pasteur Institute and the Cochin Institute of Molecular Genetics in Paris, the Free University of Brussels, Belgium, and Harvard Medical School and Massachusetts General Hospital, both in Boston.

In addition, he has more than 20 years experience as an investor and co-founder of biotechnology companies in the United States and Europe, most recently Hybrigenics, a privately held company he helped to establish in 1998 and where he served as chairman and chief executive officer from 1999 to late 2004.

“Donny’s groundbreaking research, particularly in the areas of Legionnaire’s disease, AIDS, and obesity, along with entrepreneurial skills that have led to his founding five companies, make him a perfect fit for the work we are doing at Scripps Florida,” said Scripps Research President Richard A. Lerner, M.D. “His research, combined with the latest advanced technologies, should produce significant results in fighting disease and improving human health.”

“I am delighted to participate in the development of a world-class research department at Scripps Florida, as well as help create associated innovative biotechnology companies,” said Dr. Strosberg.

Dr. Strosberg will begin his tenure at Scripps Florida March 1.

Arthur “Donny” Strosberg

Born in Montreux, Switzerland, in 1945 and a citizen of Belgium, Strosberg received his License in Chemistry in 1966 and a Doctorate in Sciences (Chemistry) in 1970 from the Free University of Brussels, Belgium.  After a postdoctoral fellowship at Massachusetts General Hospital and Harvard University, he served as an instructor and later visiting professor at Harvard Medical School. He then returned to the Free University of Brussels as a professor in protein chemistry and biochemical pathology, followed by a professorship in biochemistry and immunology at the University of Paris. From 1986 to 1990, he was chief of the unit of molecular biology of receptors at the Pasteur Institute, followed by eight years as director of the molecular immunopharmacology unit and vice president of the Cochin Institute of Molecular Genetics. 

Professor Strosberg has trained 45 Ph.D. candidates and nearly twice as many postdoctoral fellows. He has received numerous awards and honors from US and European scientific organizations; he holds nearly 20 issued patents, many of which have been licensed to pharmaceutical companies; he has published more than 370 scientific articles in the major scientific journals in his field.

Dr. Strosberg has more than 20 years experience investing in and co-founding biotechnology companies, including Chemunex SA, Nouveau Marché, Incyte and Praecis. He has served on the board of directors and scientific advisory boards of these and other companies, helping to complete successive private placement offerings as well as filing for IPO listings on public capital markets.  He has also helped to start and run three biotech incubators. He is one of the few members from the industrial sector of the investment committee of the French government’s Fund of Funds, which supports French venture capital companies.

Most recently, Dr. Strosberg has been chairman and CEO of Hybrigenics, a privately held company he helped to found in 1998, together with the Pasteur Institute. The company is a leader in functional proteomics, seeking to develop drugs against cancer, diabetes and viral diseases, with approximately 40 patent applications and a capitalization of $60 million.

Strosberg and his wife have two grown children. His hobbies include growing Bonsai trees and raising tropical fish.

About the Scripps Research Institute and Scripps Florida

The Scripps Research Institute in La Jolla, California, and Palm Beach County, Florida, is one of the world's largest, private, non-profit biomedical research organizations.  It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development.

The Scripps Research Institute employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel in 14 buildings overlooking the Pacific Ocean in the northernmost neighborhood of the City of San Diego.

Scripps Florida will be a 364,000 square-foot, state-of-the-art biomedical research facility to be built on 100 acres of undeveloped land in Palm Beach County.  The facility will focus on basic biomedical science, drug discovery, and technology development, employing more than 500 researchers and support staff by 2010. Palm Beach County and the State of Florida have provided start-up economic packages for development, building, staffing, and equipping the campus.
 
Scripps Florida is now operating out of a 40,000 square-foot facility on the campus of Florida Atlantic University in Jupiter.


For more information contact:
Office of Communications
10550 North Torrey Pines Road
La Jolla, California 92037

press@scripps.edu